Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$1.26
$1.07
$3.40
$30.33M0.2171,840 shs676,700 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$0.72
+0.2%
$0.40
$0.24
$4.47
$23.96M0.18940,517 shs615,138 shs
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$1.10
$1.09
$0.26
$1.28
$116.26M1.61957,342 shsN/A
Vaccitech plc stock logo
VACC
Vaccitech
$1.10
+28.1%
$1.57
$1.64
$5.10
$42.40M-0.4244,643 shs126,140 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
0.00%0.00%0.00%0.00%-31.38%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-0.44%+17.35%+154.03%+177.58%-75.37%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00%0.00%0.00%0.00%0.00%
Vaccitech plc stock logo
VACC
Vaccitech
+3.49%+3.61%+2.38%-11.44%-58.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
4.7638 of 5 stars
3.05.00.04.43.34.21.3
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/AN/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
3.00
Buy$14.00∞ Upside
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.00
Hold$4.25488.89% Upside
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00
N/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$16.45M0.00N/AN/A$2.20 per share0.00
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$2.84 per shareN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$94.64M1.23N/AN/A$0.56 per share1.96
Vaccitech plc stock logo
VACC
Vaccitech
$13.42M3.16$0.06 per share19.30$6.52 per share0.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
-$9.99M-$0.49N/AN/AN/A-85.75%-30.19%-27.55%N/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$98.79M-$2.51N/AN/AN/AN/A-129.80%-112.06%8/6/2025 (Estimated)
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
-$13.27M-$0.15N/AN/A-14.03%-23.82%-8.80%N/A
Vaccitech plc stock logo
VACC
Vaccitech
$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/A

Latest RLMD, VACC, SCTL, and OCUP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.31-$0.58-$0.27-$0.58N/AN/A
3/27/2025Q4 2024
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.70-$0.62+$0.08-$0.62N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/A
10.68
10.68
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
6.89
6.89
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.01
1.07
0.86
Vaccitech plc stock logo
VACC
Vaccitech
N/A
15.26
15.26

Institutional Ownership

CompanyInstitutional Ownership
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
14.97%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
87.15%
Vaccitech plc stock logo
VACC
Vaccitech
26.13%

Insider Ownership

CompanyInsider Ownership
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
8.70%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
20.70%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
7.60%
Vaccitech plc stock logo
VACC
Vaccitech
6.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
1425.92 million24.47 millionOptionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million24.74 millionOptionable
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
258105.69 million97.66 millionOptionable
Vaccitech plc stock logo
VACC
Vaccitech
3338.55 million36.23 millionNot Optionable

Recent News About These Companies

10 Startups Founded Out Of Oxford University
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
How real are the threats to the US dollar?
Google invests in UK vaccine pioneer Vaccitech
News - Leon Hooftman

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ocuphire Pharma stock logo

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$0.72 +0.00 (+0.24%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$0.72 0.00 (-0.10%)
As of 05/29/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Societal CDMO stock logo

Societal CDMO NASDAQ:SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Vaccitech stock logo

Vaccitech NASDAQ:VACC

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.